Literature DB >> 19208413

Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical myotonia.

Margherita Milone1, Sat D Batish, Jasper R Daube.   

Abstract

Genetically proven myotonic dystrophy type 2 (DM2) was found in a 61-year-old woman with creatine kinase (CK) elevation and only isolated weakness of one triceps. There was no clinical or electrical myotonia. Electromyography (EMG) showed only scattered fibrillation potentials and short duration motor unit potentials. Muscle biopsy showed nonspecific myopathic features and highly atrophic fibers with nuclear clumps. DM2 should be considered in patients with focal proximal weakness and abnormal EMG without myotonic discharges.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208413     DOI: 10.1002/mus.21150

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Diagnostic odyssey of patients with myotonic dystrophy.

Authors:  James E Hilbert; Tetsuo Ashizawa; John W Day; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

Review 2.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

3.  Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.

Authors:  Estefania Cerro-Herreros; Mouli Chakraborty; Manuel Pérez-Alonso; Rubén Artero; Beatriz Llamusí
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

4.  Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia.

Authors:  Josef Finsterer; Georg Safoschnik; Martina Witsch-Baumgartner
Journal:  SAGE Open Med Case Rep       Date:  2017-04-10

5.  Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.

Authors:  Eduardo Huarte; Roddy S O'Connor; Michael T Peel; Selene Nunez-Cruz; John Leferovich; Ashish Juvekar; Yan-Ou Yang; Lisa Truong; Taisheng Huang; Ahmad Naim; Michael C Milone; Paul A Smith
Journal:  Clin Cancer Res       Date:  2020-09-30       Impact factor: 12.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.